+34 620 10 75 37info@nanbiosis.com

News

nanbiosis news

You are here : Home / News

Resolution of the 1st competitive call of 2026 for access to NANBIOSIS

NANBIOSIS is a Research Infrastructure for Biomedicine made up of the Platforms of the Center for Centro de Ivesntigación Biomedica en Red (CIBER– in the area of Bioengineering, Biomaterials, and Nanomedicine -CIBER-BBN), the Preclinical Infrastructure and the Development of Minimally Invasive Technologies, of the Jesús Usón Minimally Invasive Surgery Center (CCMIJU) and the Nanoimaging unit of the Biomedical Research Institute of Malaga-Nanomedicine Platform (IBIMA-BIONAND Platform).

NANBIOSIS as part of the Spanish Map of ICTS (an acronym for “Scientific and Technical Unique Infrastructures” in Spanish), approved by the Ministry of Science and Innovation, is open to all interested national and international users, and who can apply for access under the “Competitive Open Access” or “Access on Demand” modalities.

20% of the capacity of the Units of NANBIOSIS is granted on the Competitive Open Access modality and will be prioritized according to scientific and technical quality and singularity of the applictions.

Click here to see the resolution of the 1st 2026 Open Call.

What is NANBIOSIS?

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

• Read More

How a tumor metabolite changes Glioma behavior and improves treatment response

A new study shows how a tumor metabolite can make aggressive glioma cells more sensitive to treatment, revealing new opportunities for therapy.

Valencia, February 2026 — A recent study published in Biomedicines shows that D-2-hydroxyglutarate (2HG), a molecule produced by certain brain tumors, can significantly change how glioma cells behave. The research demonstrates that when IDH-wildtype glioma cells are exposed to 2HG, they begin to resemble IDH-mutant tumors, becoming less aggressive and more sensitive to standard cancer treatments. The study involved the use of NANBIOSIS research infrastructure (more specifically, Unit 26), underlining its role in advanced biomedical research.

The article, titled “Isocitrate Dehydrogenase-Wildtype Glioma Adapts Toward Mutant Phenotypes and Enhanced Therapy Sensitivity Under D-2-Hydroxyglutarate Exposure” (Biomedicines, 2025), explores how tumor metabolism influences the growth, spread, and treatment response of gliomas.

What are IDH mutations and why do they matter?

Some gliomas carry mutations in a gene called isocitrate dehydrogenase (IDH). These mutations cause tumor cells to produce 2HG, a so-called “oncometabolite” that alters how cells grow and function. Interestingly, patients with IDH-mutant gliomas often respond better to treatment, but the reasons behind this have not been fully understood.

To better understand this effect, researchers compared glioma cells with and without IDH mutations. They studied how the cells behaved under low-oxygen conditions, which are common inside tumors, and how they responded to chemotherapy (temozolomide) and radiotherapy.

What did the researchers find?

The study (full reference at the end of this piece) found clear differences between the two types of tumor cells:

  • IDH-wildtype glioma cells grew faster and adapted more easily to low oxygen levels
  • IDH-mutant cells divided more slowly and showed signs of growth arrest

When IDH-wildtype cells were exposed to 2HG, however, they began to change. These cells showed slower growth, increased cell death during chemotherapy, and changes in surface markers linked to tumor aggressiveness. In other words, 2HG made aggressive tumor cells behave more like the less aggressive IDH-mutant tumors.

Evidence from animal models

The researchers also tested these effects in mouse models of glioma. Tumors formed from IDH-wildtype cells were larger and spread more into surrounding brain tissue. In contrast, tumors exposed to 2HG were smaller and more compact.

Although some tumor cells became more mobile over time, this movement was strongly reduced when chemotherapy or radiotherapy was applied. This suggests that 2HG exposure may increase the effectiveness of existing treatments.

These findings show that tumor metabolism plays a key role in how gliomas grow and respond to therapy. While IDH mutations and 2HG may initially help tumor cells survive, they also appear to make tumors more vulnerable to treatment and less invasive.

Understanding this balance could help researchers identify new treatment strategies that exploit these weaknesses, potentially improving outcomes for patients with glioblastoma and other gliomas.

NANBIOSIS infrastructure supporting the study

This research involved the use of NANBIOSIS Unit 26 (U26. NMR: Biomedical Applications II). The BMRI-3T (MR Solutions) system, registered at the Unit 26 facility of ICTS NANBIOSIS at the Universitat de València, was used for in vivo imaging studies. The authors also acknowledged Musta Ezzedin Ayoub from the UCIM–Universitat de València imaging team for his contribution to image acquisition.

NANBIOSIS Unit 26 is based at the Faculty of Medicine of the University of Valencia and provides advanced NMR and imaging technologies for biomedical research. The Unit supports studies on metabolism, disease mechanisms, and treatment response in both academic and industrial projects.

Read the full paper here.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

If you want to collaborate with us, visit our Order Request page.

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More

NANBIOSIS strengthens science–industry collaboration at Science for Industry (S4i) 2026 round table

NANBIOSIS takes part in a key S4i 2026 round table on science–industry collaboration, highlighting Spain’s science industry and technology transfer.

Madrid, February 2026 — Last week, NANBIOSIS contributed to a high-level round table at Science for Industry (S4i) 2026, an event focused on strengthening a knowledge-based economic model and accelerating the commercialization of scientific advances to boost competitiveness in Europe.

S4i 2026 advocates for high-value reindustrialization driven by science, emphasizing the transformative potential of Deep Science to foster innovation, safeguard future growth, and catalyze a significant upturn in the EU economy by shortening the path from research to market.

Round table: Science industry in Spain and the connection between research and innovation

The round table, titled “Science industry in Spain and the connection between research and innovation” explored the role and potential of the Spanish science industry ecosystem. The session brought together representatives from public administration, industry, and national research infrastructures to discuss how collaboration can promote innovation, enhance technology transfer, and create new opportunities across sectors.

Participants provided insights into current dynamics between science and industry, the specificities of the science industry market, emerging business models at the science–industry interface, and the success factors for deep tech spin-offs—particularly in biotechnology, ICT, health, and energy.

Speakers

  • Amparo López, Member of the SOMMa Executive Committee and Delegate of the SOMMa Knowledge Transfer and Innovation Working Group
  • Manuel Espinosa, General Manager at DEMEDE Engineering; Engineer & MBA with extensive experience in technology transfer, product design, and deep tech entrepreneurship
  • Leonor Mendoza, Head of Collaborative Projects at INEUSTAR, the Spanish Science Industry Association
  • Gabriel Alfranca, Head of Communications at NANBIOSIS, the Research Infrastructure in Nanomaterials, Biomaterials and Systems in Biomedicine

The roundtable was originally scheduled to be chaired by Javier Echávarri Delmás, National Industry Liaison Officer for Astronomy and Particle Physics at CDTI, who was ultimately unable to attend due to health reasons. The chair was therefore assumed by Leonor Mendoza.

Session structure and key topics

The session included an introduction and speaker presentations, followed by a moderated panel discussion addressing:

  • The mutual dependence of science and industry and current collaboration dynamics in Spain.
  • What differentiates the science industry market and why it represents a strategic opportunity for companies.
  • New business models emerging at the science–industry crossroads, including drivers and challenges, in which NANBIOSIS plays a key role.
  • Critical considerations for the success of deep tech spin-offs originating from scientific research.

By contributing to this round table at S4i 2026, NANBIOSIS reinforces its commitment to fostering collaboration between research infrastructures and industry, supporting technology transfer, and advancing innovation in nanomedicine and biomedicine within the Spanish and European ecosystems.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

If you want to collaborate with us, visit our Order Request page.

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More

NANBIOSIS advances targeted nanomedicine for Acute Myeloid Leukemia on World Cancer Day

NANBIOSIS Unit 18 contributes to two studies advancing CXCR4-targeted nanoconjugates for acute myeloid leukemia, highlighted on World Cancer Day.

On the occasion of World Cancer Day, NANBIOSIS highlights the recent publication of two scientific articles advancing a novel line of research focused on the development of targeted nanoconjugates for the treatment of acute myeloid leukemia (AML). Both studies include the active participation of NANBIOSIS Unit 18, reinforcing the Unit’s role in the preclinical development and evaluation of innovative cancer nanomedicines.

Optimizing conjugation strategies to enhance antitumor efficacy

The first study, “Conjugation strategy shapes antitumor efficacy and enables dose-sparing in non-antibody protein nanoconjugates”, addresses a key challenge in cancer nanomedicine: improving therapeutic selectivity while minimizing systemic toxicity. While antibody–drug conjugates (ADCs) are considered the gold standard in targeted therapies, their clinical limitations have driven the search for alternative approaches.

In this work, researchers evaluated how site-specific conjugation strategies influence the biodistribution and antitumor efficacy of a CXCR4-targeted multivalent protein nanocarrier loaded with the cytotoxic drug monomethyl auristatin E (MMAE). The results demonstrated that precise payload positioning significantly impacts therapeutic performance. Notably, a site-specific design achieved comparable tumor control with a four-fold lower drug load, highlighting the potential of dose-sparing strategies in next-generation protein-based nanomedicines.

Precision targeting of CXCR4⁺ leukemia cells in AML models

The second publication, “Precision targeting of CXCR4+ leukemia cells by a humanized MMAE-nanoconjugate in an AML mouse model”, focuses on overcoming chemoresistance and relapse in AML, which are largely driven by therapy-resistant leukemic stem cells in the bone marrow.

The study describes the development of T22-HSNBT-H6-MMAE, a humanized nanoconjugate designed to selectively target CXCR4-overexpressing leukemia cells, a biomarker associated with poor prognosis in approximately 50% of AML patients. In vitro and in vivo experiments demonstrated potent antileukemic activity, including complete suppression of leukemic dissemination and prolonged survival in a disseminated AML mouse model, without systemic toxicity. Importantly, the nanoconjugate showed selectivity for malignant cells while sparing healthy bone marrow and peripheral blood cells.

The role of NANBIOSIS Unit 18

NANBIOSIS Unit 18, located at the Hospital de la Santa Creu i Sant Pau (Barcelona) and coordinated by Dr. Ramón Mangues, specializes in nanotoxicology and preclinical safety assessment. The Unit evaluates the toxicity and tolerability of new drugs, nanoparticles and nanotechnology-based biomaterials using in vitro and in vivo models, supporting the optimization of lead compounds with higher probabilities of clinical success.

With advanced facilities for cell culture, flow cytometry, confocal microscopy and in vivo experimentation in small animal models, Unit 18 plays a key role in ensuring the safety, efficacy and translational potential of innovative nanomedicine approaches.

Together, these two studies underscore the contribution of NANBIOSIS to cutting-edge cancer research and highlight the promise of CXCR4-targeted nanoconjugates as a new therapeutic strategy for patients with acute myeloid leukemia.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

If you want to collaborate with us, visit our Order Request page.

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More

NANBIOSIS Unit 2 (CAbS) at the III SENTIATECH Meeting on Science, Technology & Health Risk Monitoring

NANBIOSIS Unit 2 (CAbS) participates in the III SENTIATECH Meeting, showcasing nanobiotechnology and diagnostics for health risk monitoring.

NANBIOSIS is actively represented at the III SENTIATECH Meeting | Science, Technology & Health Risk Monitoring through the Nb4D research group, in which NANBIOSIS Unit 2 “CAbS” is integrated. This third edition of the SENTIATECH Meeting focuses on presenting the SENTIATECH platform and strengthening collaboration between research centers and industry to tackle current and emerging challenges in defense and chemical–biological risk management.

During the meeting, Dr. J. Pablo Salvador, Tenured Scientist and member of the Nb4D group, is coordinating Working Group 4 (WG4), dedicated to the monitoring and diagnosis of health-related risks. This working group addresses key scientific and technological strategies for early detection, surveillance, and response to threats affecting human health.

In parallel, the Nb4D group has a dedicated exhibition space at the event, where it is presenting its research and technological capabilities in nanobiotechnology, diagnostics, and antibody-based solutions. As experts in immunoassay development, the group showcases advanced tools for the detection of pathogens, toxins, chemical contaminants, and other threatening substances, reinforcing the relevance of NANBIOSIS infrastructures in high-impact risk scenarios.

The SENTIATECH Meeting brings together stakeholders from academia, research institutions, and industry with the shared objective of:

  • Presenting technological solutions for defense and chemical–biological risk scenarios
  • Fostering collaborative synergies between science and industry
  • Defining a strategic agenda to address emerging and future risks effectively

Participation in this forum highlights the commitment of NANBIOSIS and its units to technology transfer, innovation, and the application of cutting-edge science to protect human health and security.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

If you want to collaborate with us, visit our Open Call page.

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More

Preclinical Histology Workflow within NANBIOSIS

New video shows the Preclinical Histology workflow of NANBIOSIS Unit 20 at VHIR, part of an integrated platform for preclinical validation and imaging.

NANBIOSIS has published a new video on its YouTube channel showcasing the Preclinical Histology Section, one of the key service areas of NANBIOSIS Unit 20 – In vivo Experimental Platform, located at the Vall d’Hebron Research Institute (VHIR) in Barcelona.

The Preclinical Histology Section provides specialized tissue processing and staining services for the evaluation of therapeutic compounds and biomarkers in preclinical research. Operating within ISO-certified facilities, the team works with both paraffin-embedded and OCT-embedded frozen samples, offering high-level expertise in histological staining, immunohistochemistry, and immunofluorescence.

The video focuses on the paraffin-embedded sample workflow, demonstrating each step of the process: reception and classification of formalin-fixed samples, automated tissue processing, paraffin embedding, precise block orientation, microtome sectioning, and hematoxylin–eosin staining. The section routinely handles a wide range of biological materials, from whole organs to delicate tissues and advanced 3D models such as organoids, ensuring reproducibility and high-quality results.

Importantly, the Preclinical Histology Section is part of the broader NANBIOSIS Unit 20, which comprises three integrated sections: Molecular Imaging, Preclinical Animal Models, and Preclinical Histology. All three are embedded within the Functional Validation & Preclinical Research (FVPR) area of CIBBIM-Nanomedicine. This integrated structure enables Unit 20 to offer comprehensive preclinical proof-of-concept validation services.

Led by Dr. Ibane Abasolo, Head of FVPR, Unit 20 stands out for combining toxicology, histopathology, and efficacy studies with non-invasive optical imaging technologies, including in vivo bioluminescence and fluorescence imaging. This unique combination allows longitudinal monitoring of living animal models, providing real-time insights into treatment efficacy, biodistribution, and mechanisms of action. While similar imaging technologies exist elsewhere in Spain, Unit 20 is unique in offering them fully integrated with dedicated preclinical animal models.

This new video offers a practical glimpse into the high-quality preclinical services available through NANBIOSIS Unit 20.
More information about the unit and its full service portfolio is available on the NANBIOSIS website.

https://www.youtube.com/shorts/PwYuCOJALlE

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

If you want to collaborate with us, visit our Open Call page.

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More

NANBIOSIS Launches Its Official Newsletter

By subscribing to our Newsletter, you will receive curated updates straight to your inbox.

We are pleased to announce the launch of the NANBIOSIS Newsletter, a new communication channel designed to keep our community up to date with the most relevant news and opportunities from our infrastructure.

By subscribing to our Newsletter, you will receive curated updates straight to your inbox every three months, featuring selected content you won’t want to miss. We value your time: we do not spam, and the Newsletter will only be sent to users who actively subscribe.

👉 If you wish to receive future editions, you can subscribe here.

Celebrating 10 Years of NANBIOSIS as an ICTS: Highlights of 2025

To mark the 10th anniversary of NANBIOSIS as a Unique Scientific and Technical Infrastructure (ICTS), our first Newsletter includes a selection of key highlights from 2025:

Featured News

NANBIOSIS Strengthens Internal Collaboration at the 2025 Networking Event in Cáceres
A networking event bringing together Units working in biomaterials, nanomedicine, and biomedical research to foster collaboration. Read the article.

Revalidated as a Unique Scientific and Technical Infrastructure (ICTS)
In November 2025, NANBIOSIS was revalidated as a Spanish ICTS, reaffirming its strategic role in cutting-edge innovation. Read the article.

Danish Students Visit NANBIOSIS Unit 28 (NanoImaging) at IBIMA-BIONAND
International students explored advanced nanoimaging technologies driving innovation in biomedical research. Read the article.

In addition to other interesting scientific highlights. You can read the entire newsletter here.

Stay connected and don’t miss future updates: subscribe to the NANBIOSIS Newsletter and follow the latest developments from our Units, researchers, and infrastructures.

And do not forget, this is the last week for our Open Call! More information here.

Mark your calendar and ready your proposals! The Call is open until the end of January 2026. You can access to it here.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More

Ready your proposals: Open Call starts on january

NANBIOSIS opens in January the 1st Competitive Open Call of 2026 for our “Cutting-Edge Biomedical Solutions” and services.

Last year we made two Open Calls, and it was about time to introduce you to the first call of 2026: offering you our discounts and preferential access during the entire month of January! You can access to it here.

Our publicly funded facilities and internationally renowned scientists will help you design and test biomedical solutions to your heart’s content. We are open to all interested national and international users who may come either from the public or the private sector. You can apply to use our services in two modalities: under the “Competitive Open Access” (within our two designated yearly calls) or by “Access on Demand”, your choice.

To make that happen, at least 20% of the capacity of the Units of NANBIOSIS is offered on the Competitive Open Access modality. The proposals granted under this modality will be prioritized according to criteria of scientific and technical quality and singularity. In addition, a 5% discount will be applied for those proposals that resort to at least one of our integrated services, the Cutting-Edge Biomedical Solutions. The call can be accessed here.

NANBIOSIS is a research infrastructure for Biomedicine included in the the Spanish Map of ICTS (Spanish for “Scientific and Technical Unique Infrastructures”), approved by the Spanish Ministerio de Ciencia, Innovación y Universidades.

There are 2 calls per year for Competitive Open Access that allow the prioritization of the best proposals. Click here to apply.

As stated, the next call will open on January 2026. The applications can be submitted throughout the whole month (due date January 31th). Access application forms submitted after that date will be processed under the “Access on Demand” modality.

Proposals granted in the Competitive Open Access modality must meet, at least, one of the circumstances listed in the access application form (“order request“), in order to demonstrate their scientific and technical quality or singularity.

Thus, for example, applications related to R&D projects funded through national or European calls are eligible. In addition, the proposals are required to use one of the NANBIOSIS “Cutting-Edge Biomedical Solutions”. That implies the interaction of at least two of our Units. The choice of said Units can be modified to your specific needs.

Mark your calendar and ready your proposals! The Call is open until the end of January 2026. You can access to it here.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More

NANBIOSIS Revalidated as a Unique Scientific and Technical Infrastructure (ICTS) in Spain

NANBIOSIS has been revalidated as a Spanish ICTS in November 2025, reaffirming its strategic role in cutting-edge biomedical research and innovation.

Valencia, November 2025 — Last month, the Government of Spain reaffirmed NANBIOSIS as an Infraestructura Científico-Técnica Singular (ICTS), confirming its status as a key national infrastructure supporting cutting-edge research, technological development, and innovation in biomedicine and nanotechnology.

The ICTS designation is granted to publicly owned scientific and technical infrastructures that are unique or exceptional, require high investment and operational resources, and provide open and competitive access to the entire R&D&I community. These infrastructures play a strategic role in enabling frontier research, facilitating knowledge generation and preservation, promoting technology transfer, and fostering innovation.

ICTS are distributed throughout Spain and are included in the Map of Unique Scientific and Technical Infrastructures, a dynamic framework that ensures infrastructures continuously meet strict excellence, accessibility, and quality requirements. Depending on their level of integration, ICTS may operate as single-site facilities, networks of infrastructures, or distributed infrastructures.

The revalidation of NANBIOSIS as an ICTS highlights its sustained scientific excellence, public-service mission, and strategic relevance within the Spanish research ecosystem. This recognition reinforces the commitment of NANBIOSIS to offering advanced services and state-of-the-art capabilities to academic researchers, healthcare institutions, and industrial partners.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More

NANBIOSIS U26 Contributes to New Study Using CMR and PET to Track Myocardial Infarction Progression in Mice

Multimodal CMR/PET imaging reveals key differences in infarct evolution in mice. NANBIOSIS U26 contributed technical expertise and advanced imaging support.

Valencia, December 2025 — A new scientific publication, “Characterization of Infarct Size and Remodeling Using CMR and PET in Mice Models of Reperfused and Non-Reperfused Myocardial Infarction” (Diagnostics, 2025), highlights the value of combining cardiovascular magnetic resonance (CMR) and positron emission tomography (PET) for non-invasive, longitudinal evaluation of heart damage in preclinical models of myocardial infarction. The study features the participation of NANBIOSIS Unit 26, which contributed both technical expertise and advanced imaging infrastructure.

A multimodal approach to understanding Heart Injury

The research compares two experimental mouse models of myocardial infarction—one with permanent coronary occlusion (non-reperfused) and another with transient occlusion followed by reperfusion. Using CMR and fluorine-18 FDG PET imaging at baseline and at 1, 7, and 21 days after infarction, the authors assessed:

  • Infarct size
  • Systolic function
  • Myocardial glucose metabolism

Masson’s trichrome histology served as the reference standard for infarct size at the chronic phase.

The results showed that both models exhibited infarction, reduced systolic function, and decreased glucose metabolism as early as 24 hours post-event. By day 21, reperfused mice demonstrated smaller infarcts and better-preserved cardiac function, although metabolic activity measured by PET did not differ significantly between groups. Moreover, early CMR and PET measurements proved to be strong predictors of long-term outcomes.

These findings underscore the value of combined PET/CMR imaging for monitoring disease progression and evaluating new therapeutic strategies in preclinical cardiovascular research.

NANBIOSIS Participation

NANBIOSIS Unit 26 (NMR Biomedical Applications II) played an essential role in the project by providing both expert technical support—via technician and co-author Mustafa Ezzeddin—and access to its specialized imaging facilities.

“To continue advancing the Biomedical and Metabolomics Imaging section, we are pleased to share that we have published an article using a murine model of acute myocardial infarction, employing 3T MRI and PET-CLIP-ON techniques.”

—Mustafa Ezzeddin, technician at Unit 26 of NANBIOSIS

About NANBIOSIS Unit 26

Located at the Faculty of Medicine of the University of Valencia (UV), Unit 26 offers advanced NMR-based metabolomic and imaging capabilities, including a 14T NMR system for biofluid, cell line, and tissue metabolic profiling. The Unit is coordinated by Dr. Ramón Martínez-Máñez, Principal Investigator of the Applied Molecular Chemistry Group at the Universitat Politècnica de València and Scientific Director of NANBIOSIS, together with Dr. Salvador Gil, Director of the Central Service for Experimental Research (SCSIE).

Reference: DOI

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More